IVIg vs PE
Number of patients with adverse events attributed to treatment · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number of participants with adverse events attributed to treatment compared with PE (moderate certainty).
1 finding from 1 review
- RR 0.84 [0.54, 1.3]4 studies · 388 participantsModerate